Iricryn

Bimatoprost, the active ingredient in Iricryn, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is used to manage open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Iricryn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iricryn is a prostaglandin analog indicated for conditions that require reduction of intra‑ocular pressure.

Open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression. Ocular hypertension: reduces elevated eye pressure to prevent development of glaucoma. Secondary ocular hypertension: helps control pressure when caused by other ocular conditions.

Bimatoprost may cause a range of ocular and peri‑ocular reactions.

Common Side Effects: - Conjunctival hyperemia (eye redness). - Increased eyelash length and thickness. - Eye irritation or foreign‑body sensation. - Blurred vision, especially after instillation. - Darkening of the iris or peri‑ocular skin. - Mild ocular discomfort or itching.

Serious or Rare Side Effects: - Anterior uveitis or iritis. - Cystoid macular edema. - Severe allergic reaction (e.g., angio‑edema). - Sudden loss of vision. - Persistent ocular pain. - Corneal endothelial decompensation.

Before prescribing Iricryn, clinicians should consider several safety measures.

Monitor intra‑ocular pressure regularly: ensure therapeutic effect and detect over‑reduction. Avoid use in active ocular infection or inflammation: may exacerbate condition. Caution in patients with corneal endothelial dysfunction: risk of corneal edema. Pregnancy Category C: discuss potential risks with pregnant or nursing patients. Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Bimatoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analog eye drops: additive pressure‑lowering effect. - Systemic carbonic anhydrase inhibitors combined with other IOP‑lowering drugs: risk of excessive hypotension. - Use with ocular corticosteroids in patients prone to macular edema.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: may mask systemic beta‑blocker effects. - Anticholinergic agents: monitor for pupil dilation and angle‑closure risk.